Last reviewed · How we verify
Huperzine A for Injection
Huperzine A for Injection, marketed by Jiangsu Famous Medical Technology Co., Ltd., holds a distinct position in the pharmaceutical market with its unique mechanism of action and primary indication. The drug's key strength lies in its protected intellectual property, with the key composition patent expiring in 2028, providing a significant barrier to entry for competitors. The primary risk is the lack of detailed revenue data and key trial results, which may limit the drug's market valuation and investor confidence.
At a glance
| Generic name | Huperzine A for Injection |
|---|---|
| Sponsor | Jiangsu Famous Medical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury (PHASE4)
- Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Huperzine A for Injection CI brief — competitive landscape report
- Huperzine A for Injection updates RSS · CI watch RSS
- Jiangsu Famous Medical Technology Co., Ltd. portfolio CI